The Menarini Group (Menarini), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group, announced that Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), Stemline’s development partner in Japan, received Orphan Drug Designation for tagraxofusp, from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the expected indication of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
BPDCN is an aggressive orphan hematologic malignancy with historically poor clinical outcomes. Stemline’s Elzonris (tagraxofusp) is the only approved treatment for patients with BPDCN, and the first and only approved CD123-targeted therapy, in both the United States and Europe.
Orphan drugs are designated by Japan’s MHLW for treatments that are intended for use in fewer than 50,000 patients, where there is also a particularly high medical need. Orphan drug designation can potentially shorten the period required to obtain regulatory approval in Japan by several months, thereby enabling faster patient access.
In Japan, tagraxofusp is being developed by Nippon Shinyaku, which is currently conducting a phase 1/2 clinical trial. In March 2021, Stemline and Nippon Shinyaku entered into an exclusive licensing agreement for the development and commercialization of tagraxofusp in Japan, including the possibility of co-promotion.
“The MHLW’s decision to grant Orphan Drug Designation recognizes the potential positive impact tagraxofusp could have on BPDCN patients in Japan, a patient population that currently has limited treatment options,” said Elcin Barker Ergun, CEO of the Menarini Group. “This achievement by our partner, Nippon Shinyaku, advances our commitment to bring transformative new therapeutic options to patients with difficult-to-treat cancers, and to deliver innovative medicines to people around the globe.”
BPDCN, formerly blastic NK-cell lymphoma, is an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes. BPDCN typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera. The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. The diagnosis of BPDCN is based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers. The World Health Organization (WHO) termed this disease “BPDCN” in 2008; previous names included blastic NK cell lymphoma and agranular CD4+/CD56+ hematodermic neoplasm.
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4.4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia.
Stemline Therapeutics, Inc. (Stemline) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics.
Nippon Shinyaku’s mission is to help people lead healthier and happier lives. Through creating unique medicines that will bring hope to patients and families struggling with illness, the company aim to be an organization trusted by the community.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!